Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.

Trial Profile

Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2012

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top